| Literature DB >> 25852055 |
Dorothée Selimoglu-Buet1, Orianne Wagner-Ballon2, Véronique Saada3, Valérie Bardet4, Raphaël Itzykson5, Laura Bencheikh1, Margot Morabito6, Elisabeth Met6, Camille Debord4, Emmanuel Benayoun2, Anne-Marie Nloga7, Pierre Fenaux7, Thorsten Braun8, Christophe Willekens9, Bruno Quesnel10, Lionel Adès7, Michaela Fontenay4, Philippe Rameau11, Nathalie Droin12, Serge Koscielny13, Eric Solary1.
Abstract
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/ myeloproliferative neoplasm whose diagnosis is currently based on the elevation of peripheral blood monocytes to >1 × 10(9)/L, measured for ≥3 months. Diagnosis can be ambiguous; for example, with prefibrotic myelofibrosis or reactive monocytosis. We set up a multiparameter flow cytometry assay to distinguish CD14(+)/CD16(-) classical from CD14(+)/CD16(+) intermediate and CD14(low)/CD16(+) nonclassical monocyte subsets in peripheral blood mononucleated cells and in total blood samples. Compared with healthy donors and patients with reactive monocytosis or another hematologic malignancy, CMML patients demonstrate a characteristic increase in the fraction of CD14(+)/CD16(-) cells (cutoff value, 94.0%). The associated specificity and sensitivity values were 95.1% and 90.6% in the learning cohort (175 samples) and 94.1% and 91.9% in the validation cohort (307 samples), respectively. The accumulation of classical monocytes, which demonstrate a distinct gene expression pattern, is independent of the mutational background. Importantly, this increase disappears in patients who respond to hypomethylating agents. We conclude that an increase in the fraction of classical monocytes to >94.0% of total monocytes is a highly sensitive and specific diagnostic marker that rapidly and accurately distinguishes CMML from confounding diagnoses.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25852055 PMCID: PMC4497970 DOI: 10.1182/blood-2015-01-620781
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113